

Market Applicability/Effective Date														
Market	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	N/A	N/A	X	N/A	X	X	X	X	X	X	N/A	N/A	X

*FHK- Florida Healthy Kids

Noctiva (desmopressin acetate) Intranasal Spray

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Noctiva (desmopressin acetate) Intranasal Spray	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Noctiva (desmopressin acetate) intranasal spray may be approved when the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual has been diagnosed with nocturnal polyuria; **AND**
- III. Diagnosis has been confirmed by a 24-hour urine collection which notes the presence of greater than 1/3 (one-third) of 24 hour urine production occurring at night; **AND**
- IV. Individual awakens at least two (2) times per night to void; **AND**
- V. Individual has been evaluated for causes of nocturia, such as but not limited to overactive bladder, obstructive sleep apnea, diabetes mellitus, benign prostatic hyperplasia, congestive heart failure, and excessive evening fluid intake and treatment has been optimized for these conditions; **AND**
- VI. Individual has documented normal serum sodium level based on laboratory reference range within the previous 60 days.

Requests for Noctiva (desmopressin acetate) intranasal spray **may not** be approved when any of the following criteria are present:

- I. Hyponatremia or history of hyponatremia; **OR**
- II. Polydipsia; **OR**
- III. Primary nocturnal enuresis; **OR**
- IV. Concomitant use with loop diuretics or systemic or inhaled glucocorticoids; **OR**
- V. Estimated glomerular filtration rate (GFR) below 50 mL/min/1.73m²; **OR**
- VI. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) ; **OR**
- VII. During illnesses that can cause fluid or electrolyte imbalance; **OR**
- VIII. New York Heart Association (NYHA) Class II-IV congestive heart failure (CHF); **OR**
- IX. Uncontrolled hypertension.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability/Effective Date														
Market	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	N/A	N/A	X	N/A	X	X	X	X	X	X	N/A	N/A	X

*FHK- Florida Healthy Kids

NOTE: Noctiva (desmopressin acetate) has a black box warning regarding the potential for hyponatremia, which may be life-threatening if severe. Noctiva is contraindicated in those at risk for severe hyponatremia. Serum sodium should be normal before starting or resuming Noctiva. Serum sodium should be measured within seven days and one month after starting Noctiva, and periodically during treatment. Those 65 years of age and older should be more frequently monitored. Noctiva may need to be temporarily or permanently discontinued if hyponatremia occurs.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2017. URL:

<http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website.

<http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed January 30, 2017.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2017; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.